Stocktoria
Zura Bio Ltd ZURA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-16
Chart by TradingView
2/9
Piotroski F — financial health
3.48
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Operating income | -$75.2M | -$55.2M | -$62.6M | -$27.2M |
| Net income | -$68.7M | -$52.4M | -$60.4M | -$25.7M |
| Operating cash flow | -$64.8M | -$28.1M | -$15.1M | -$1.2M |
| Free cash flow | -$64.9M | -$28.2M | — | — |
| Total assets | $113.9M | $179.5M | $100.8M | $5.3M |
| Total liabilities | $12.4M | $19.5M | $21.3M | $14.8M |
| Shareholders' equity | $101.5M | $148.4M | $60.9M | -$32.1M |
| Ratios | ||||
| Return on assets | -60.2% | -29.2% | -59.9% | -489.1% |
| Return on equity | -67.6% | -35.3% | -99.2% | 80.3% |
| Current ratio | 9.05 | 9.16 | 4.97 | 0.12 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.48 (safe)
- Working capital / assets 0.877
- Retained earnings / assets -1.971
- EBIT / assets -0.66
- Equity / liabilities 8.182
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001855644 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.